Olema Pharmaceuticals, Inc.
OLMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001750284
In the last 90 days, Olema Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 185 institutions reported holding it in 13F filings for Q2 2026, worth $1.28B in total; Duquesne Family Office is the only superinvestor holding it.
Holders of 5% or more of OLMA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Olema Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 12.50%10.0M shares | +6.20 ppfrom 6.30% | Feb 5, 20262 filings | Mar 6, 2026 | SEC |
| Bain Capital Life Sciences Opportunities IV, L.P. | 13G/A | 9.99%8.51M shares | 0.00 ppfrom 9.99% | Jan 13, 20253 filings | Feb 17, 2026 | SEC |
| Paradigm Biocapital Advisors LP | 13G/A | 9.99%7.43M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| Janus Henderson Group PLC | 13G/A | 8.40%6.71M shares | +3.20 ppfrom 5.20% | Nov 14, 20252 filings | Feb 17, 2026 | SEC |
| Invus Global Management, LLC | 13G | 5.10%4.46M shares | New | Mar 20, 20261 filing | Mar 20, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
13 Schedule 13D and 13G filings on Olema Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 20, 202610:37 AM ET | Invus Global Management, LLCand 7 others | 13G | 5.10%4.46M shares | New | Mar 16, 2026 | SEC |
| Mar 6, 202610:05 AM ET | FMR LLCand 1 other | 13G/A | 12.50%10.0M shares | +6.20 ppfrom 6.30% | Feb 27, 2026 | SEC |
| Feb 17, 20264:34 PM ET | Janus Henderson Group PLC | 13G/A | 8.40%6.71M shares | +3.20 ppfrom 5.20% | Dec 31, 2025 | SEC |
| Feb 17, 20264:30 PM ET | Bain Capital Life Sciences Opportunities IV, L.P. | 13G/A | 9.99%8.51M shares | 0.00 ppfrom 9.99% | Dec 31, 2025 | SEC |
| Feb 13, 20268:49 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 0.00%0 shares | −5.04 ppfrom 5.04%Below 5% | Dec 31, 2025 | SEC |
| Feb 5, 20261:31 PM ET | FMR LLCand 1 other | 13G | 6.30%5.02M shares | New | Dec 31, 2025 | SEC |
| Nov 14, 202510:29 AM ET | Janus Henderson Group PLC | 13G | 5.20%3.59M shares | New | Sep 30, 2025 | SEC |
| May 15, 20253:51 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 2.30%1.54M shares | –Below 5% | Mar 31, 2025 | SEC |
| May 15, 20258:46 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 5.04%3.44M shares | – | Mar 31, 2025 | SEC |
| May 15, 20257:00 AM ET | Bain Capital Life Sciences Opportunities IV, L.P. | 13G/A | 9.99%6.84M shares | 0.00 ppfrom 9.99% | Mar 31, 2025 | SEC |
| May 13, 20257:29 PM ET | Logos Global Management LPand 5 others | 13D/A | 4.70%3.21M shares | –Below 5% | Mar 18, 2025 | SEC |
| Feb 14, 20254:45 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G/A | 9.99%7.43M shares | – | Dec 31, 2024 | SEC |
| Jan 13, 20254:24 PM ET | Bain Capital Life Sciences Opportunities IV, L.P. | 13G/A | 9.99%7.10M shares | – | Jan 8, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Olema Pharmaceuticals, Inc. shares.
No Form 144 notices for Olema Pharmaceuticals, Inc. are on file.